Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)

NCT05203458 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05203458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
February 24, 2022
Completion date
July 5, 2023
Enrollment
3,136 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2